medigraphic.com
ISSN 0016-3813 (Impreso)

2016, Número 6

<< Anterior Siguiente >>

Gac Med Mex 2016; 152 (6)


La actividad funcional de los transportadores ABCB1 (P-gp) y ABCG2 (BCRP1) en pacientes con artritis reumatoide (AR) está determinada por la actividad de la enfermedad (AE)

Pascual-Ramos V, Atisha-Fregoso Y, Lima G, Fragoso-Loyo H, Jákez-Ocampo J, Contreras-Yáñez I, Llorente L

Idioma: Español
Referencias bibliográficas: 49
Paginas: 741-754
Archivo PDF: 299.60 Kb.


RESUMEN

Antecedentes: La P-gp y el BCRP1 son transportadores cuya actividad se asocia a resistencia a fármacos. Objetivo: Comparar la actividad de ambos en pacientes con AR activos e inactivos y definir la relación con la AE. Métodos: Se incluyeron 17 pacientes activos pareados (edad, sexo y seguimiento) con 17 inactivos, con evaluaciones en el momento del ingreso; 27 tenían evaluación a los seis meses. La actividad de P-gp y BCRP1 se midió en mononucleares de sangre periférica por citometría de flujo y se expresó como el porcentaje de linfocitos que expulsó el sustrato en presencia/ausencia de inhibidores. Se solicitó consentimiento informado. Se aplicó estadística descriptiva y modelos de regresión lineal. Resultados: Los pacientes activos tuvieron mayor actividad de ambos transportadores que aquéllos inactivos: mediana (Q25-Q75) para P-gp de 7.1% (1.4-29.3) versus 1.6% (0.7-3.5); y para BCRP1, de 6.2% (1.3-22.4) versus 1.3% (0.7-2); (p ≤ 0.02). En el momento del ingreso, la AE determinó la actividad de ambos transportadores. A los seis meses, los cambios en la AE se correlacionaron con los cambios en la actividad de P-gp (r = 0.35; p = 0.07) y BCRP1 (r = 0.33; p = 0.09). Conclusiones: Los pacientes activos tuvieron mayor actividad de P-gp y BCRP1 que los inactivos. La AE pareciera determinar la actividad de ambos transportadores.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Goda K, Bacsó Z, Szabó G. Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets. 2009;9:281-9.

  2. Ueda K, Cornwell MM, Gottesman MM, et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun. 1986;141:956-62.

  3. Litman T, Druley TE, Stein WD, et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci. 2001;58:931-59.

  4. Mohri H, Markowitz M. In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J Acquir Immune Defic Syndr. 2008;48:511-21.

  5. Jansen G, Scheper RJ, Dijkmans BA. Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. Scand J Rheumatol. 2003;32:325-36.

  6. Fleming A, Benn RT, Corbert M, Wood PH. Early rheumatoid disease. II. Patterns of joint involvement. Ann Rheum Dis. 1976;35:361-4.

  7. Emery P, Salmon M. Early rheumatoid arthritis: to aim for remission? Ann Rheum Dis. 1995;54:944-7.

  8. Paulus HE. Defining remission in rheumatoid arthritis: what is it? Does it matter? J Rheumatol. 2004;31:1-4.

  9. O’Dell JR. Treatment of Rheumatoid Arthritis. En: Imboden JB, Hellmann DB, Stone JH, editores. Current Rheumatology Diagnosis & Treatment. Nueva York: McGraw-Hill Inc; 2007. p. 170-4.

  10. Pélaez-Ballestas I, Sanin LH, Moreno-Montoya J, et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011;86:3-8.

  11. Mody GM, Cardiel MH. Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol. 2008; 22:621-41.

  12. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum. 2004;50:709-15.

  13. Möttönen T, Hannonen P, Korpela M, et al. Delay of Institution of therapy or induction of remission using single drug or combination-disease- modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;46:894-8.

  14. Nell VPK, Machold KP, Eberl G. Benefit of very early referral therapy with disease modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43:906-14.

  15. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001;44:2009-17.

  16. Paulus HE, van der Heijde DM, Bulpitt KJ, Gold RH. Monitoring radiographic changes in early rheumatoid arthritis. J Rheumatol. 1996;23:16-24.

  17. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69: 1580-8.

  18. Coopere NJ. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology. 2000;39:28-33.

  19. Young A, Dixey J, Kulinskaya E, et al. Which patients with early arthritis stop working? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis. 2002;61:335-40.

  20. Cardiel MH, Díaz-Borjón A, Vázquez del Mercado Espinosa M, et al. Actualización en la guía mexicana para el tratamiento farmacológico de la artritis reumatoide del colegio mexicano de reumatología. Reumatol Clin. 2014;10:227-40.

  21. Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol. 2005;72:46-7.

  22. Llorente L, Richaud-Patin Y, Díaz-Borjón A, et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine. 2000;67:30-9.

  23. Maillefert JF, Maynadie M, Tebib JG, et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol. 1996;35:430-5.

  24. Jorgensen C, Sun R, Rossi JF, et al. Expression of multidrug resistance gene in human rheumatoid synovium. Rheumatol Int. 1995;15:83-6.

  25. Borowski LC, Lopes RP, González TP, et al. Is steroid resistance related to multidrug resistance-I (MDR-I) in rheumatoid arthritis? Int Immunopharmacol. 2007;7:836-44.

  26. Wolf J, Stranzl T, Filipits M, et al. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:564-8.

  27. Hider SL, Owen A, Hartkoorn R, et al. Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. Ann Rheum Dis. 2006;65:1390-3.

  28. Furst DE. Acquired resistance of human T cells to sulfasalazine. Ann Rheum Dis. 2004;63:115-6.

  29. Van der Heijden J, de Jong MC, Dijkmans BAC, et al. Acquires resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis. 2004; 63:131-7.

  30. Van der Heijden J, de Jong MC, Dijkmans BAC, et al. Development of sulfasalazine resistance in human T cells induces expression of the myultidrug resistance transporter ABCG2 (BCRP) and augmented production of TNF alpha. Ann Rheum Dis. 2004;63:138-43.

  31. Pascual-Ramos V, Contreras-Yáñez I, Villa-Moreno AR, Cabiedes-Conteras J, Rull-Gabayet M. Medication persistence over 2-years follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity. Arthritis Res Ther. 2009;11:R26.

  32. Estrada J, Pascual-Ramos V, Martínez B, Uribe M, Torre A. Autoimmune hepatitis with giant-cell transformation. Case report. Ann of Hepatol. 2009;8:68-70.

  33. Pascual-Ramos V, Contreras-Yañez I, Rull-Gabayet M, Villa AR, Vázquez-Lamadrid J, Mendoza-Ruiz JJ. Hypervascular sinovitis and American College of Rheumatology classification criteria as predictors of radiographic damage in early rheumatoid arthritis. USQ. 2009;25:31- 8.

  34. Contreras-Yáñez I, Ponce de León S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease modifying anti-rheumatic drugs. Am J Med Sci. 2010;340: 282-90.

  35. Contreras-Yáñez I, Cabiedes J, Villa AR, Rull-Gabayet M, Pascual-Ramos V. Persistence on therapy is a major determinant of patient-, physician-, and laboratory-reported outcomes in recent onset rheumatoid arthritis patients. Clin Exp Rheumatol. 2010;28:748-51.

  36. Contreras-Yáñez I, Rull-Gabayet M, Vázquez-Lamadrid J, Pascual-Ramos V. Radiographic outcome in Hispanic early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs. Eur J Radiol. 2011;79:52-7.

  37. Contreras-Yáñez I, Rull-Gabayet M, Pascual-Ramos V. Early disease activity suppression and younger age predict excellent outcome of recent- onset rheumatoid arthritis patients with conventional disease modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2012;30:402-8.

  38. Pascual-Ramos V, Contreras-Yáñez I. Motivations for inadequate persistence with disease modifying anti-rheumatic drugs. The patient´s perspective. BMC Musculoskelet Disord. 2013;14:336.

  39. Sánchez T, Elías-López D, Contreras-Yáñez I, Aguilar-Salinas C, Pascual- Ramos V. Prevalence of lipid phenotypes, serum lipid´s behavior over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizos early rheumatoid arthritis (RA) patients treated with conventional DMARDs. Clin Exp Rheumatol. 2014;32:509-15.

  40. Parra-Salcedo F, Contreras-Yáñez I, Elías-López D, Aguilar-Salinas A, Pascual-Ramos V. Prevalence, incidence and characteristics of the Metabolic Syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis (RA) patients treated with conventional disease modifying anti- rheumatic drugs. The complex relationship between MetS and disease activity. Arthritis Res Ther. En prensa 2015.

  41. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.

  42. Prevoo ML. Modified disease activity scores that include twenty-eightjoint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.

  43. Van de Ven R, Oerlemans R, van der Heijden JW, et al. ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J Leuk Biol. 2009;86:1075-9.

  44. Márki-Zay J, Jakab T, Szerémy P, Krajcsi P. MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013;31:779-87.

  45. Machold KP, Stamm TA, Nell VPK, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatol. 2007;46:342-9.

  46. Kroot EJJA, de Wong BAW, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent- onset rheumatoid arthritis. Arthritis Rheum. 2000;43:1831-5.

  47. Yudoh K, Matsumo H, Nakazawa F, Yonezawa T, Kimura T. Increased expression of multidrug resistance of P-glycoprotein on Th1 cells correlates with drug resistance in rheumatoid arthritis. Arthritis Rheum. 1999;42:2014-5.

  48. Kapplemayer J, Karazi E, Telek B, Jakab K. “Pros and cons” on how to measure multidrug resistance in leukemias. Leuk Lymphoma. 2002;43: 711-7.

  49. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012;19:1946-2025.




2020     |     www.medigraphic.com